Sonnet BioTherapeutics (NASDAQ:SONN), Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cytokine-based therapies to address significant unmet needs in oncology and inflammatory diseases. Since its founding in 2016, Sonnet has leveraged proprietary protein engineering platforms to create targeted immunomodulatory molecules designed to enhance efficacy while reducing systemic toxicity. The company is headquartered in New York City and operates research and development facilities in both the United States and Europe.
At the core of Sonnet’s pipeline are next-generation cytokine therapeutics that engage the immune system with precision. By fusing select cytokine moieties with targeting domains, Sonnet aims to concentrate immune activity at sites of disease, including solid tumors and sites of chronic inflammation. Its lead candidates have entered early- to mid-stage clinical trials, where they are being evaluated both as monotherapies and in combination with checkpoint inhibitors. Beyond oncology, Sonnet is advancing programs in autoimmune and fibrotic conditions, applying the same targeted delivery approach to rebalance immune responses.
Sonnet maintains a global development footprint, conducting clinical studies across North America, Europe and the Asia-Pacific region. The company has established strategic collaborations with academic institutions and global biopharmaceutical partners to accelerate its translational research and expand access to diverse patient populations. In addition, Sonnet’s manufacturing strategy incorporates both in-house process innovation and partnerships with leading contract development and manufacturing organizations (CDMOs) to support scalable production as programs advance toward potential registration.
Leadership at Sonnet BioTherapeutics combines deep expertise in immunology, protein engineering and clinical development. The executive team includes seasoned professionals who have held senior roles at leading biotech and pharmaceutical companies, supported by a board of directors with extensive experience in drug discovery, regulatory affairs and strategic partnering. Together, this leadership cadre is guiding Sonnet’s commitment to bring differentiated cytokine therapies from the laboratory to patients in need.
